Acquired by Alfasigma S.p.A. Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. Show more
Location: | Website: www.interceptpharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
0.00
52 Wk Range
$N/A - $N/A
Previous Close
$19.00
Open
$19.00
Volume
N/A
Day Range
$19.00 - $19.00
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
3.13%
Institutional Own.
81.30%
Qtr Updated
06/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OCALIVA® (obeticholic acid) Details Primary biliary cholangitis, Infectious disease, COVID-19, Liver disease | Approved Quarterly sales | |
Ocaliva + Bezafibrate Details Primary biliary cholangitis, Liver disease | Phase 2 Update | |
INT-787 Details Liver disease, Alcoholic hepatitis | Phase 2a Update | |
Ocaliva Details Non-alcoholic steatohepatitis , Liver disease | Failed Discontinued | |
Ocaliva Details Primary sclerosing cholangitis, Liver disease | Failed Discontinued | |
Ocaliva Details Non-alcoholic steatohepatitis , Liver disease | Failed Discontinued |